Review of Endocrinology Month: March 2024.

Published Date: 07 Apr 2024

March 20,24: Endocrinology Month in Review.

Read Full News

Latest News

Converting Basal Insulin Patients to Insulin Icodec Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss switching patients from basal insulin to Awiqli.

Insulin Icodec Dosing Strategies for Type 2 Diabetes Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the commercial release of insulin icodec.

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

Q4 2026 Preview: 7 FDA Decisions to Watch

Q4 2026 Preview: 7 FDA Decisions to Watch

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss switching patients from basal insulin to Awiqli.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the commercial release of insulin icodec.

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

Q4 2026 Preview: 7 FDA Decisions to Watch

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

News All Time

TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia Ryan Livingston

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation Ryan Livingston

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD Ryan Livingston

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes Marc P. Bonaca, MD, MPH

The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.

Insulin Icodec Now Available for Type 2 Diabetes in US Ryan Livingston

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

Diabetes Dialogue: Tech, Screening, and Care Highlights from ADCES 2026 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

Diabetes Dialogue hosts recap ADCES26 highlights on insulin delivery tech, CKM care, C-peptide science, ketone monitoring, and hypercortisolism screening.

New Patch Pump Options Highlighted at ADCES 2026 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss new insulin pump technology presented at ADCES 2026.

Continuous Ketone Monitoring May Guide SGLT2i Use in T1D Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the promise of continuous ketone monitoring in T1D.

Avexitide Reduces Hypoglycemic Events in Phase 3 LUCIDITY Trial for PBH Ryan Livingston

The phase 3 trial showed a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo, meeting all secondary endpoints.

The HCPFive: Top News for Healthcare Providers from the Week of 08/16 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including a new lerodalcibep FDA approval and phase 3 avexitide data in post-bariatric hypoglycemia.

Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes Ryan Livingston

Abbott's Libre Duo 10 Day earned FDA De Novo authorization, becoming the first continuous dual glucose-ketone monitor for diabetes.

FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes

FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes

FDA Clears Beta Bionics' Mint Insulin Patch Pump for Diabetes Ryan Livingston

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

Tirzepatide Gets FDA Approval to Cut Cardiovascular Risk in Type 2 Diabetes Abigail Brooks, MA

SURPASS-CVOT showed tirzepatide is non-inferior to dulaglutide for cardiovascular events in more than 13,000 adults with type 2 diabetes.

Recommended News For You

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Race, Geography Linked to Gaps in Prostate Cancer Care

Novel probes to label macrophages associated with cancer progression using a selective dye

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Time to Rethink Maintenance Pemetrexed in NSCLC?

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Recommended Articles For You

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment 

Circulating Tumor DNA Dynamics for Therapy Matching: A Comprehensive Clinical Review 

Quality of Life Through Personalized Survivorship Navigation After Multimodal Cancer Therapy 

Screening for Early Changes in Blood-Cell Production Capacity in Older Adults 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TULSA Is Effective in Long-Term Prostate Cancer Control.

2.

AVD Chemo Regimen Shows Promise in Older Patients With HL

3.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

4.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

5.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

1.

Programmable Cell Therapies for Selective Removal of Dysfunctional Hematopoietic Cell Populations

2.

Contemporary Insights in Oncology in the Digital Era

3.

Strategic Concepts in Hematology for Modern Medicine

4.

Ferroptosis-Modulating Therapeutics in Precision Oncology

5.

Exploring the Potential of Bendamustine in Cancer Treatment

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

2.

Blood Clotting Disorders Explained

3.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

4.

Chemotherapy: What to Expect

5.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot